Skip to main content
. 2020 Oct 14;12:10113–10125. doi: 10.2147/CMAR.S271807

Figure 1.

Figure 1

The relationship between CBX3 expression and clinicopathological data. (A and B) Differential expression of CBX3 in normal stomach and gastric cancer tissues. (C and D) Evaluation of the sensitivity and specificity of gastric cancer diagnosis by ROC curves. (E) Expression of CBX3 in normal gastric tissues, precancerous lesions and gastric cancer tissues in the GSE26690 dataset. (F) Changes of CBX3 expression in various cells in single-cell sequencing GSE134520 dataset. (G) Immunohistochemical staining for CBX3 in gastric cancer tissues (n=30). (H) Semiquantitative immunity score in gastric cancer tissues and paracancerous tissues. (IL) The association of CBX3 expression levels with T stage, tumor location, microsatellite instability and positive lymph nodes in the cohort TCGA-STAD. P value designations: ns: P≥ 0.05, *P < 0.05, ****P < 0.0001.